KIT and diabetes mellitus: Imatinib, a Tyrosine kinase inhibitor, was found to be a target drug for KIT. Previous studies point out that imatinib could potentially influence related immunological and metabolic pathways, and preclinical investigations demonstrate that it can both reverse and prevent diabetes (Gitelman et al., 2021).